Legislation & Advocacy

Advocacy Efforts

Americans for Ibogaine is committed to advancing policies that support FDA-approved ibogaine research in the United States. We work to educate lawmakers, researchers, and key stakeholders on ibogaine’s potential as a breakthrough treatment for substance use disorder and mental health conditions. By advocating for science-backed regulatory pathways, we aim to position the U.S. as a leader in ibogaine research and expand access to innovative treatment options for those in need.

State Initiatives

ARIZONA

COLORADO

  • In November 2022, Colorado voters approved Proposition 122, known as the Natural Medicine Health Act, which decriminalized the possession, cultivation, and sharing of certain natural medicines, including ibogaine, for adults aged 21 and over.

  • Following this, the Colorado General Assembly enacted Senate Bill 23-290 in 2023 to establish a regulatory framework for these substances. This legislation allows for the inclusion of ibogaine in the state's natural medicine program, contingent upon recommendations from the Natural Medicine Advisory Board and approval by the Director and the Executive Director of the State Licensing Authority. leg.colorado.gov

  • As of now, ibogaine is not yet available for therapeutic use in Colorado. The state is in the process of developing the necessary regulations and infrastructure to incorporate ibogaine into its natural medicine program, with the potential for its inclusion in the future. dpo.colorado.gov

  • For more detailed information on the implementation timeline and the current status of ibogaine in Colorado, refer to the Department of Regulatory Agencies' Natural Medicine Health Act Implementation Timeframe. dpo.colorado.gov

KENTUCKY

MISSISSIPPI

NEW YORK

  • New York State has introduced Senate Bill S1817, which mandates the Office of Addiction Services and Supports (OASAS) to facilitate clinical research into ibogaine as a potential treatment for heroin, methamphetamine, and cocaine addiction.  This initiative follows a previous effort in the state to study ibogaine's use in treating PTSD among veterans and first responders.  

  • Read the bill here: SENATE BILL S1817

OHIO

TEXAS

WASHINGTON

  • Washington State has introduced Senate Bill 5201, which would fund a three-year study on ibogaine’s efficacy for opioid use disorder. The bill has bipartisan support from legislators, including Jesse Salomon (D), T'wina Nobles (D), Jessica Bateman (D), Yasmin Trudeau (D), Liz Lovelett (D), Noel Frame (D), Mike Chapman (D), Robert Hasegawa (D), Lisa Wellman (D), Rebecca Saldaña (D), Jeff Holy (R), Curtis King (R), Mark Schoesler (R), and Jeff Wilson (R).

  • Read the bill here:  SENATE BILL 5201

Federal Path

At the federal level, ibogaine is classified as a Schedule I-controlled substance, indicating it is currently illegal and not approved for medical use in the United States. However, recent developments show a growing interest in exploring its potential therapeutic benefits.

We are monitoring these developments and advocating for federal policies that facilitate research into ibogaine’s therapeutic potential.

Find Your Representative

Your voice matters in the fight for ibogaine research and access. Use the tool below to find your U.S. Senators and Representatives and tell them you support FDA-approved clinical trials for ibogaine. Educating lawmakers about ibogaine’s potential to address substance use disorder and mental health conditions is crucial to advancing research and expanding access. 

Countries Where Ibogaine is Accessible

The legal status of ibogaine varies worldwide. In some countries, it is legal or unregulated, allowing for its use in medical or therapeutic settings:

Understanding the global legal landscape of ibogaine is crucial for informing advocacy and research efforts.